作者
Ehsan Irajizad,Ana Kenney,Tiffany M. Tang,Jody Vykoukal,Ranran Wu,Eunice Murage,Jennifer B. Dennison,Marta Sans,James P. Long,Maureen Loftus,John A. Chabot,Michael D. Kluger,Fay Kastrinos,Lauren K. Brais,Ana Babić,Kunal Jajoo,Linda Lee,Thomas E. Clancy,Kimmie Ng,Andrea J. Bullock,Jeanine M. Genkinger,Anirban Maitra,Kim‐Anh Do,Bin Yu,Brian M. Wolpin,Samir Hanash,Johannes F. Fahrmann
摘要
Emerging evidence implicates microbiome involvement in the development of pancreatic cancer (PaCa). Here, we investigate whether increases in circulating microbial-related metabolites associate with PaCa risk by applying metabolomics profiling to 172 sera collected within 5 years prior to PaCa diagnosis and 863 matched non-subject sera from participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cohort. We develop a three-marker microbial-related metabolite panel to assess 5-year risk of PaCa. The addition of five non-microbial metabolites further improves 5-year risk prediction of PaCa. The combined metabolite panel complements CA19-9, and individuals with a combined metabolite panel + CA19-9 score in the top 2.5th percentile have absolute 5-year risk estimates of >13%. The risk prediction model based on circulating microbial and non-microbial metabolites provides a potential tool to identify individuals at high risk of PaCa that would benefit from surveillance and/or from potential cancer interception strategies.